1
|
Li H, Lu C, Liu Z, Xiang F, Liu B, Wang H, Chang J, Pan L, Chen Y, Chen J. Advancements in bioscavenger mediated detoxification of organophosphorus poisoning. Toxicol Res (Camb) 2024; 13:tfae089. [PMID: 38863796 PMCID: PMC11163184 DOI: 10.1093/toxres/tfae089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Accepted: 06/04/2024] [Indexed: 06/13/2024] Open
Abstract
Background Organophosphorus compounds, widely used in agriculture and industry, pose a serious threat to human health due to their acute neurotoxicity. Although traditional interventions for organophosphate poisoning are effective, they often come with significant side effects. Objective This paper aims to evaluate the potential of enzymes within biological organisms as organophosphorus bioclearing agents. It analyses the technical challenges in current enzyme research, such as substrate specificity, stereoselectivity, and immunogenicity, while exploring recent advancements in the field. Methods A comprehensive review of literature related to detoxifying enzymes or proteins was conducted. Existing studies on organophosphorus bioclearing agents were summarised, elucidating the biological detoxification mechanisms, with a particular focus on advancements in protein engineering and novel delivery methods. Results Current bioclearing agents can be categorised into stoichiometric and catalytic bioclearing agents, both of which have shown some success in preventing organophosphate poisoning. Technological advancements have significantly improved various properties of bioclearing agents, yet challenges remain, particularly in substrate specificity, stereoselectivity, and immunogenicity. Future research will focus on expanding the substrate spectrum, enhancing catalytic efficiency, prolonging in vivo half-life, and developing convenient administration methods. Conclusion With the progression of clinical trials, bioclearing agents are expected to become widely used as a new generation of therapeutic organophosphate detoxifiers.
Collapse
Affiliation(s)
- Hexi Li
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
- Unit No. 31666 of PLA, 1 New City Courtyard, Jinyang Town, Liangzhou District, Wuwei, Gansu 733000, China
| | - Cong Lu
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
- Unit No. 94347 of PLA, 24 Wenfu Road, Shenhe District, Shenyang, Liaoning 110000, China
| | - Zhenmin Liu
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
| | - Fengshun Xiang
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
| | - Bo Liu
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
| | - Hongjuan Wang
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
| | - Jie Chang
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
| | - Li Pan
- State Key Laboratory of NBC Protection for Civilians, 30 South Central Street, Yangfang Town, Changping District, Beijing 102205, P. R. China
| | - Youwei Chen
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
| | - Jingfei Chen
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
- Unit No. 32169 of PLA, 100 Shuangyong East Road, Nyingchi, Tibet 860000, China
| |
Collapse
|
2
|
Organophosphate detoxification by membrane-engineered red blood cells. Acta Biomater 2021; 124:270-281. [PMID: 33529769 DOI: 10.1016/j.actbio.2021.01.043] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 01/22/2021] [Accepted: 01/26/2021] [Indexed: 12/31/2022]
Abstract
Biotherapeutics have achieved global economic success due to their high specificity towards their drug targets, providing exceptional safety and efficiency. The ongoing shift away from small molecule drugs towards biotherapeutics heightens the need to further improve the pharmacokinetics of these biological drugs. Three pervasive obstacles that limit the therapeutic capacity of biotherapeutics are proteolytic degradation, circulating half-life, and the development of anti-drug antibodies. These challenges can culminate in limited efficiency and consequently warrant the need for higher drug doses and more frequent administration. We have explored the coupling of biotherapeutics to long-lived and biocompatible red blood cells (RBCs) to address limited pharmacokinetics. Butyrylcholinesterase (BChE), for example, provides prophylactic protection against organophosphate nerve agents (OPNAs), yet the short circulation life of the drug requires extraordinary doses. Herein, we report the rapid and tunable chemical engineering of BChE to RBC membranes to create a cell-based delivery system that retains the enzyme activity and enhances stability. In a three-step process that first pre-modifies BChE with a cell-reactive polymer chain, primes the cells for engineering, and then grafts the conjugates to the cells, we attached over 2 million BChE molecules to the surface of each RBC without diminishing the bioscavenging capacity of the enzyme. Critically, this membrane-engineering approach was cell-tolerated with minimal hemolysis observed. These results provide strong evidence for the ability of engineered RBCs to serve as an enhanced biotherapeutic delivery vehicle. STATEMENT OF SIGNIFICANCE: Organophosphate nerve agents (OPNAs) are one of the most lethal forms of chemical warfare. After exposure to OPNAs, a patient is given life-saving therapeutics, such as atropine and oxime. However, these drugs are limited, and the patient can still suffer from irreparable injuries. Given the toxicity of OPNAs, access to a prophylactic is vital. We have created an enhanced delivery system for prophylactic butyrylcholinesterase (BChE) by engineering this biotherapeutic to the red blood cell (RBC) surface. In three simple steps that first pre-modifies BChE with a cell-reactive polymer, primes the cells for engineering, and then grafts the conjugates to the cells, we attached over 2 million BChE molecules to a single RBC while retaining the enzyme's activity and enhancing its stability.
Collapse
|
3
|
Rosenberg Y, Saxena A. Acetylcholinesterase inhibition resulting from exposure to inhaled OP can be prevented by pretreatment with BChE in both macaques and minipigs. Neuropharmacology 2020; 174:108150. [PMID: 32442543 PMCID: PMC7365266 DOI: 10.1016/j.neuropharm.2020.108150] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Revised: 05/05/2020] [Accepted: 05/14/2020] [Indexed: 10/24/2022]
Abstract
More frequent and widespread nerve agent attacks highlight the need for efficacious pre- and post-exposure organophosphate (OP) counter-measures to protect military and civilian populations. Because of critical targeting of acetylcholinesterase (AChE) in the CNS by OPs, a pre-treatment candidate for preventing/reducing poisoning will be a broadly acting molecule that scavenges OPs in blood before they reach their physiological targets. Prophylactic human butyrylcholinesterase (HuBChE), the leading pretreatment candidate, has been shown to protect against multiple LD50's of nerve agents in rodents, macaques, and minipigs. This review describes the development of a HuBChE bioscavenger pretreatment from early proof-of-concept studies to pre-clinical studies with the native injectable enzyme and the development of aerosolized forms of recombinant enzyme, which can be delivered by inhalation nebulizer devices, to effect protection against inhaled OP nerve agents and insecticides. Early animal studies utilized parenteral exposure. However, lungs are the portal of entry for most volatile OP vapors and represent the major means of OP intoxication. In this regard, pretreat-ment with 7.5 mg/kg of HuBChE by IM injection protected minipigs against lethal sarin vapor and prevented AChE inhibition in the blood. This is similar to the five-day protection in macaques by an aerosolized rHuBChE using a nebulizer against aerosolized paraoxon (estimated to be an 8 mg/kg estimated human dose). Importantly, lethal inhaled doses of OP may be smaller relative to the same dose delivered by injection, thus reducing the protective HuBChE dose, while a combination of HuBChE and post-exposure oxime may prolong protection.
Collapse
Affiliation(s)
| | - Ashima Saxena
- U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD, 20910, USA
| |
Collapse
|